The START Center for Cancer Research, its preclinical arm XenoSTART, and Denmark-based Minerva Imaging have expanded their decade-long partnership to create an integrated platform for radiopharmaceutical drug development. The collaboration combines XenoSTART’s clinically annotated patient-derived xenograft (PDX) models with Minerva’s molecular imaging and radionuclide therapy capabilities.  Radiopharmaceuticals are gaining momentum in oncology, particularly in metastatic prostate cancer,...